title: Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension?
authors.affiliation: Department of Medical Oncology, Paris Descartes University, School of Medicine, Cochin-Port Royal, Paris.
authors.forename: G
authors.initials: G
authors.lastname: Emile
authors.affiliation: Department of Medical Oncology, Paris Descartes University, School of Medicine, Hotel Dieu Hospital, Assistance Publique-Hopitaux de Paris, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.affiliation: Department of Medical Oncology, Paris Descartes University, School of Medicine, Cochin-Port Royal, Paris jerome.alexandre@cch.aphp.fr.
authors.forename: J
authors.initials: J
authors.lastname: Alexandre
mesh_terms: D000577:Amides / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015331:Cohort Studies; D018572:Disease-Free Survival; D057915:Drug Substitution; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy* / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020913:Perindopril / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D012008:Recurrence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000577:Amides; D000806:Angiotensin-Converting Enzyme Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005650:Fumarates; D047428:Protein Kinase Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C446481:aliskiren; D004656:Enalapril; D020913:Perindopril